Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: a multicenter prospective study

Zeng, Hongmei; Cao, Maomao; Xia, Changfa; Wang, Dongmei; Chen, Kun; Zhu, Zheng; Fu, Ruiying; Zhang, Shaokai; Zhou, Jinyi; Wang, Huadong; Qi, Xianyun; Dai, Shuguang; Chen, Yong; Sun, Zhong; Ding, Hao; Li, Qingwen; Zhao, Hui; Zhang, Xuehong; Morze, Jakub; Ji, John S.; Sun, Feng; Yu, Xueqin; Qu, Chunfeng; Chen, Wanqing

doi:10.1038/s43018-023-00618-8

Cited by 6 publications

(3 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The models assumed that within-stage survival is worse for symptomatically detected cancers vs. screen-detected cancers, which is clinically plausible and consistent with the findings of screening studies. 13 , 14 …”

Section: Methodsmentioning

confidence: 99%

Benefits and harms of polygenic risk scores in organised cancer screening programmes: a cost-effectiveness analysis

Xia,

Xu,

et al. 2024

The Lancet Regional Health - Western Pacific

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Benefits and harms of polygenic risk scores in organised cancer screening programmes: a cost-effectiveness analysis

Xia,

Xu,

et al. 2024

The Lancet Regional Health - Western Pacific

Self Cite

View full text Add to dashboard Cite

“…[ 15 16 17 18 ] Although conclusive evidence on the reduction in HCC mortality through screening is lacking, our recent multicenter prospective study confirmed that screening among HBV-infected populations significantly improved HCC survival, highlighting the “real-world” feasibility and effectiveness of HCC screening for the early detection of HCC and for improving survival. [ 19 ] One of the goals of the Healthy China 2030 program is to increase the 5-year nationwide cancer survival rate through cancer prevention and screening by 2030. Expanding the coverage of HCC screening and improving HCC survival rates are crucial for achieving this goal.…”

Section: Introductionmentioning

confidence: 99%

Survey of hepatitis B virus infection for liver cancer screening in China: A population-based, cross-sectional study

Xu,

Xia,

et al. 2024

Chinese Medical Journal

Self Cite

View full text Add to dashboard Cite

Background: Hepatitis B virus (HBV) infection is the primary cause of hepatocellular carcinoma (HCC) in China. The target population for HCC screening comprises individuals who test positive for hepatitis B surface antigen (HBsAg). However, current data on the prevalence of HBV infection among individuals who are eligible for HCC screening in China are lacking. We aimed to assess the seroepidemiology of HBV infection among Chinese individuals eligible for HCC screening to provide the latest evidence for appropriate HCC screening strategies in China. Methods: Questionnaires including information of sex, age, ethnicity, marital status, educational level, source of drinking water, as well as smoking and alcohol consumption history and serum samples were collected from females aged 45–64 years and males aged 35–64 years in 21 counties from 4 provinces in eastern and central China between 2015 and 2023. Enzyme-linked immunosorbent assay methods were used to detect the serum HBV marker HBsAg. Results: A total of 603,082 individuals were enrolled, and serum samples were collected for analysis from January 1, 2015 to December 31, 2023. The prevalence of HBsAg positive in the study population was 5.23% (31,528/603,082). The prevalence of HBsAg positive was greater in males than in females (5.60% [17,660/315,183] vs. 4.82% [13,868/287,899], χ2 = 187.52, P <0.0001). The elderly participants exhibited a greater prevalence of HBV infection than younger participants (χ2 = 41.73, P <0.0001). Birth cohort analysis revealed an overall downward trend in HBV prevalence for both males and females. Individuals born in more recent cohorts exhibited a lower prevalence of HBV infection as compared to those born earlier. Conclusions: The current prevalence of HBV infection remains above 5% in populations eligible for HCC screening in China. Further efforts should be made to increase the accessibility of HCC screening among individuals with HBV infection.

show abstract

“…Hepatitis B virus (HBV) infection presents with a range of clinical manifestations, such as chronic hepatitis, cirrhosis, and acute hepatitis, which is also one of the major risk factors for the development of hepatocellular carcinoma. − The hepatitis B surface antigen (HBsAg) is a key protein located on the envelope of the HBV. It is generally the earliest biomarker detectable in the bloodstream following HBV exposure, serving as a reliable indicator of active viral infection .…”

mentioning

confidence: 99%

Neural Network Enables High Accuracy for Hepatitis B Surface Antigen Detection with a Plasmonic Platform

Sun,

Nan,

et al. 2024

Nano Lett.

View full text Add to dashboard Cite

The detection of hepatitis B surface antigen (HBsAg) is critical in diagnosing hepatitis B virus (HBV) infection. However, existing clinical detection technologies inevitably cause certain inaccuracies, leading to delayed or unwarranted treatment. Here, we introduce a label-free plasmonic biosensing method based on the thickness-sensitive plasmonic coupling, combined with supervised deep learning (DL) using neural networks. The strategy of utilizing neural networks to process output data can reduce the limit of detection (LOD) of the sensor and significantly improve the accuracy (from 93.1%−97.4% to 99%−99.6%). Compared with widely used emerging clinical technologies, our platform achieves accurate decisions with higher sensitivity in a short assay time (∼30 min). The integration of DL models considerably simplifies the readout procedure, resulting in a substantial decrease in processing time. Our findings offer a promising avenue for developing high-precision molecular detection tools for point-of-care (POC) applications.

show abstract

Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: a multicenter prospective study

Cited by 6 publications

References 60 publications

Benefits and harms of polygenic risk scores in organised cancer screening programmes: a cost-effectiveness analysis

Benefits and harms of polygenic risk scores in organised cancer screening programmes: a cost-effectiveness analysis

Survey of hepatitis B virus infection for liver cancer screening in China: A population-based, cross-sectional study

Neural Network Enables High Accuracy for Hepatitis B Surface Antigen Detection with a Plasmonic Platform

Contact Info

Product

Resources

About